NCT04265521 is a NA clinical trial of Biocool Footcare in Foot Fungus, sponsored by Biocool AB.

Who is sponsoring NCT04265521?

NCT04265521 is sponsored by Biocool AB.

What drugs are being tested in NCT04265521?

Interventions in NCT04265521: Biocool Footcare.

What condition does NCT04265521 study?

NCT04265521 studies Foot Fungus, Tinea, Tinea Pedis, Mycoses, Skin Diseases.

Is NCT04265521 still recruiting?

NCT04265521 is currently completed. Last updated 15 February 2021.

Last reviewed 2021-02-15 · How we verify

NCT04265521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet

Completed NA Last updated 15 February 2021

What this trial tests

NA trial testing Biocool Footcare in Foot Fungus in 25 participants. Completed in 25 June 2020.

Timeline

3 March 2020

Primary endpoint
26 May 2020

25 June 2020

Quick facts

Lead sponsor	Biocool AB
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	3 March 2020
Primary completion	26 May 2020
Estimated completion	25 June 2020
Sites	2 locations across Sweden

Drugs / interventions tested

Biocool Footcare

Conditions studied

Foot Fungus — all drugs for Foot Fungus →
Tinea — all drugs for Tinea →
Tinea Pedis — all drugs for Tinea Pedis →
Mycoses — all drugs for Mycoses →

Sponsor

Biocool AB

Who can join

18 and older, any sex, with Foot Fungus or Tinea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective, open, post-market study that will enroll male and female subjects diagnosed with foot fungus and at least one of the following conditions: heel cracks, calluses and/or dry feet. The investigation will consist of approximately 48 subjects (considering a 10% drop-out/screening failure rate) fulfilling the eligibility criteria for the study. Each subject will be treated with the study product, BioCool Footcare (footbath), for 3 weeks. The study duration is estimated to 5 months including recruiting, treatment and follow-up period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Biocool AB trials

Trials by the same sponsor.

NCT05046899 — Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04265521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Biocool AB
Last refreshed: 15 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04265521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing